CD20 is the ideal target antigen of B-cell lymphoma, and the combination therapy with a CD20-specific monoclonal antibody, such as rituximab with CHOP, is often used as first-line therapy for both NHL and other non-Hodgkin’s lymphomas clinically, which can effectively improve the activity of T cells and improve the immune function of the body and the therapeutic effect against the disease. This evidence concerns the gene MS4A1 and B-cell non-Hodgkin lymphoma.